LabCorp has received an Emergency Use Authorization (EUA) from the FDA for a high-throughput COVID-19 molecular test that doesn’t require reagents for extracting RNA from the samples.

The test instead uses a heat-based extraction process that is as sensitive at the conventional reagent-based extraction methods.  

The innovative extraction method improves testing efficiency and reduces reliance on testing supplies, LabCorp said.